AEON Biopharma, Inc. (AEON) Form 424B4 — Jul 15, 2026
AEON Biopharma is pricing a public offering of 17.85 million shares of common stock and pre-funded warrants to purchase 24.84 million shares, accompanied by two-year and five-year milestone warrants. The combined public offering price is $0.3221 per share of common stock and $0.3220 per pre-funded warrant, with gross proceeds expected to be approximately $13.75 million before underwriting discounts. The company intends to use the net proceeds of roughly $12.2 million for working capital and general corporate purposes, specifically to fund comparative analytical testing on ABP-450 to support biosimilarity to BOTOX.
Key figures
- Cash Position
- $19,336,000
- Gross Proceeds
- $13,747,516.61
- Shares Outstanding
- 68,995,818
- Net proceeds
- $12,880,165.61
- Greenshoe shares
- 6403291
- Warrant coverage
- 200%
- Accumulated deficit
- $482,612,000
- Common shares offered
- 17851599
- Offering price common
- $0.3221
- Offering price pre funded
- $0.3220
- Pre funded warrants offered
- 24837008
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.